Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$13.81 USD

13.81
10,278,351

+0.56 (4.23%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $13.80 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TEVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Teva Pharmaceutical Industries Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 3,226 2,801 2,165 2,177 1,975
Receivables 3,408 3,696 4,529 4,581 5,676
Notes Receivable 0 0 0 0 0
Inventories 4,021 3,833 3,818 4,403 4,422
Other Current Assets 1,829 1,721 2,059 1,844 1,391
Total Current Assets 12,485 12,051 12,573 13,005 13,464
Net Property & Equipment 5,750 5,739 5,982 6,296 6,436
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 1,812 1,453 596 695 386
Intangibles 22,564 23,903 27,506 29,547 36,078
Deposits & Other Assets 470 441 515 538 591
Total Assets 43,479 44,006 47,666 50,640 57,470
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 2,602 1,887 1,686 1,756 1,718
Current Portion Long-Term Debt 1,672 2,109 1,426 3,188 2,345
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 3,382 2,717 2,771 2,465 2,562
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 4,591 4,755 5,144 5,757 7,048
Total Current Liabilities 12,247 11,469 11,027 13,164 13,674
Mortgages 0 0 0 0 0
Deferred Taxes/Income 606 548 784 964 1,096
Convertible Debt 0 0 0 0 0
Long-Term Debt 18,161 19,103 21,617 22,731 24,562
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 4,019 3,847 2,578 2,240 2,640
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 35,353 35,315 36,422 39,579 42,407
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 57 57 57 57 56
Capital Surplus 27,807 27,688 27,561 27,443 27,312
Retained Earnings -13,534 -12,882 -10,529 -10,946 -6,956
Other Equity -2,077 -2,044 -1,717 -1,364 -1,221
Treasury Stock 4,128 4,128 4,128 4,128 4,128
Total Shareholder's Equity 8,126 8,691 11,244 11,061 15,063
Total Liabilities & Shareholder's Equity 43,479 44,006 47,666 50,640 57,470
Total Common Equity 8,126 8,691 11,244 11,061 15,063
Shares Outstanding 1,121.00 1,110.90 1,103.30 1,092.10 1,092.10
Book Value Per Share 7.25 7.82 10.19 10.13 13.79

Fiscal Year End for Teva Pharmaceutical Industries Ltd falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 3,226 2,249 2,669 2,143
Receivables NA 3,408 3,385 3,539 3,435
Notes Receivable NA 0 0 0 0
Inventories NA 4,021 4,051 4,109 4,118
Other Current Assets NA 1,829 1,739 1,770 1,805
Total Current Assets NA 12,485 11,425 12,088 11,501
Net Property & Equipment NA 5,750 5,622 5,712 5,751
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 1,812 1,748 1,578 1,572
Intangibles NA 22,564 22,410 22,856 23,763
Deposits & Other Assets NA 470 477 443 450
Total Assets NA 43,479 42,088 43,095 43,456
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 2,602 2,280 2,508 2,381
Current Portion Long-Term Debt NA 1,672 1,479 1,980 1,023
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 3,382 3,271 2,949 2,699
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 4,591 4,362 4,406 4,309
Total Current Liabilities NA 12,247 11,394 11,843 10,411
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 606 544 534 550
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 18,161 18,495 18,698 19,668
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 3,818 3,973 3,869
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 35,353 34,576 35,387 34,844
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 57 57 57 57
Capital Surplus NA 27,807 27,780 27,748 27,719
Retained Earnings NA -13,534 -13,870 -13,950 -13,086
Other Equity NA -2,077 -2,328 -2,021 -1,950
Treasury Stock NA 4,128 4,128 4,128 4,128
Total Shareholder's Equity NA 8,126 7,512 7,708 8,612
Total Liabilities & Shareholder's Equity NA 43,479 42,088 43,095 43,456
Total Common Equity 0 8,126 7,512 7,708 8,612
Shares Outstanding 1,121.00 1,121.00 1,120.90 1,120.60 1,120.40
Book Value Per Share 0.00 7.25 6.70 6.88 7.69